XML 19 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9

Collaborative Research and Development Agreements - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended	1 Months Ended	3 Months Ended
	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2011	Oct. 31, 2011	Dec. 31, 2012	Mar. 31, 2015	Aug. 31, 2014	Sep. 30, 2013	Jun. 30, 2012	May 31, 2012	Aug. 31, 2010
Deferred Revenue Arrangement [Line Items]
Revenue from milestone payment	$ 8,000,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized	$ 5,400,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized	$ 3,000,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Astra Zeneca
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue				3,000,000us-gaap_ProceedsFromCollaborators / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember
Deferred revenue recognition period			33 months
Deferred revenue	12,800,000us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember					12,300,000us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember
National Institutes of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable							200,000us-gaap_GrantsReceivable / us-gaap_CounterpartyNameAxis = dvax_NationalInstitutesOfHealthMember
National Institutes of Health | Hepatic Fibrosis and Cirrhosis
Deferred Revenue Arrangement [Line Items]
Grants receivable								200,000us-gaap_GrantsReceivable / us-gaap_CounterpartyNameAxis = dvax_NationalInstitutesOfHealthMember / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_HepaticFibrosisAndCirrhosisMember
National Institutes of Health | Autoimmune Disease
Deferred Revenue Arrangement [Line Items]
Grants receivable									600,000us-gaap_GrantsReceivable / us-gaap_CounterpartyNameAxis = dvax_NationalInstitutesOfHealthMember / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_AutoimmuneDiseaseMember
National Institutes of Health | Rheumatoid Arthritis
Deferred Revenue Arrangement [Line Items]
Grants receivable										400,000us-gaap_GrantsReceivable / us-gaap_CounterpartyNameAxis = dvax_NationalInstitutesOfHealthMember / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_RheumatoidArthritisMember
National Institute of Allergy and Infectious Diseases | Hepatitis B Virus
Deferred Revenue Arrangement [Line Items]
Grants receivable											1,400,000us-gaap_GrantsReceivable / us-gaap_CounterpartyNameAxis = dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = dvax_HepatitisBVirusMember
Amendment
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue	8,000,000us-gaap_ProceedsFromCollaborators / us-gaap_StatementScenarioAxis = dvax_AmendmentMember	5,400,000us-gaap_ProceedsFromCollaborators / us-gaap_StatementScenarioAxis = dvax_AmendmentMember			6,000,000us-gaap_ProceedsFromCollaborators / us-gaap_StatementScenarioAxis = dvax_AmendmentMember
Amendment | Maximum
Deferred Revenue Arrangement [Line Items]
Additional revenue recognized						$ 100,000,000us-gaap_DeferredRevenueRevenueRecognized / us-gaap_RangeAxis = us-gaap_MaximumMember / us-gaap_StatementScenarioAxis = dvax_AmendmentMember

X

- Definition

Revenue recognition period.

+ References

No definition available.

+ Details

Name:	dvax_RevenueRecognitionPeriod
Namespace Prefix:	dvax_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name:	us-gaap_GrantsReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementScenarioAxis=dvax_AmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: